The U.S. government is spending far too little on efforts to commercialize quantum technologies. Its SBIR and STTR programs ...
Genmab is revamping its executive team as the Danish antibody specialist expands its commercialization efforts and looks to evolve into “a fully integrated biotech innovation powerhouse.” Genmab’s ...
The next new product that will revolutionize the world—or simply help a customer in their everyday life—is out there being developed today. The question is whether it will actually make it to market.
The previous chapter provided descriptive evidence around the landscape of SBIR/STTR winners. This report now turns to the observable impact of the DOE SBIR/STTR programs on key dimensions of ...
This article explores the steps taken to commercializing flexible hybrid electronics, including an example of an FHE solution that has already come on to the market. The starting point for roadmaps ...